NextCure (NASDAQ:NXTC) Lowered to “Sell” Rating by Wall Street Zen

Wall Street Zen cut shares of NextCure (NASDAQ:NXTC) from a hold rating to a sell rating in a report released on Saturday morning.

Several other brokerages also recently commented on NXTC. Weiss Ratings downgraded shares of NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 7th. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of NextCure in a report on Wednesday. Finally, Zacks Research raised NextCure from a “strong sell” rating to a “hold” rating in a research note on Thursday, June 11th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $19.00.

NextCure Stock Down 2.9%

Shares of NASDAQ NXTC opened at $5.99 on Friday. NextCure has a 52 week low of $1.55 and a 52 week high of $15.74. The firm’s fifty day moving average is $4.43 and its 200 day moving average is $9.30. The company has a market cap of $21.64 million, a price-to-earnings ratio of -0.35 and a beta of 1.42.

NextCure (NASDAQ:NXTC) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.87) EPS for the quarter, beating analysts’ consensus estimates of ($2.10) by $0.23. Equities research analysts anticipate that NextCure will post -7.89 earnings per share for the current year.

Institutional Trading of NextCure

Large investors have recently added to or reduced their stakes in the stock. Cable Car Capital LP raised its holdings in NextCure by 13.1% in the 2nd quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock worth $349,000 after purchasing an additional 88,040 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of NextCure by 18.6% during the 4th quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock valued at $329,000 after purchasing an additional 3,636 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of NextCure by 18.7% during the 4th quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock valued at $477,000 after purchasing an additional 5,300 shares in the last quarter. Exome Asset Management LLC purchased a new position in shares of NextCure during the fourth quarter valued at about $2,341,000. Finally, AWM Investment Company Inc. purchased a new position in shares of NextCure during the fourth quarter valued at about $1,665,000. Institutional investors own 42.65% of the company’s stock.

About NextCure

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.